SI2029524T1 - Postopek za izdelavo 2-(4-(3- in 2-fluorobenziloksi)benzilamino)propanamidov - Google Patents

Postopek za izdelavo 2-(4-(3- in 2-fluorobenziloksi)benzilamino)propanamidov

Info

Publication number
SI2029524T1
SI2029524T1 SI200731603T SI200731603T SI2029524T1 SI 2029524 T1 SI2029524 T1 SI 2029524T1 SI 200731603 T SI200731603 T SI 200731603T SI 200731603 T SI200731603 T SI 200731603T SI 2029524 T1 SI2029524 T1 SI 2029524T1
Authority
SI
Slovenia
Prior art keywords
benzylaminoć
fluorobenzyloxy
production
propan amides
propan
Prior art date
Application number
SI200731603T
Other languages
English (en)
Slovenian (sl)
Inventor
Elena Barbanti
Carla Caccia
Patricia Salvati
Francesco Velardi
Tiziano Ruffilli
Luigi Bogogna
Original Assignee
Newron Pharmaceuticals S.P.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37101658&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SI2029524(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Newron Pharmaceuticals S.P.A. filed Critical Newron Pharmaceuticals S.P.A.
Publication of SI2029524T1 publication Critical patent/SI2029524T1/sl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/02—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having nitrogen atoms of carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
    • C07C233/08—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having nitrogen atoms of carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals with carbon atoms of carboxamide groups bound to acyclic carbon atoms of a saturated carbon skeleton containing rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C231/00—Preparation of carboxylic acid amides
    • C07C231/12—Preparation of carboxylic acid amides by reactions not involving the formation of carboxamide groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/12—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by halogen atoms or by nitro or nitroso groups
    • C07C233/13—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by halogen atoms or by nitro or nitroso groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C231/00—Preparation of carboxylic acid amides
    • C07C231/10—Preparation of carboxylic acid amides from compounds not provided for in groups C07C231/02 - C07C231/08
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C231/00—Preparation of carboxylic acid amides
    • C07C231/16—Preparation of optical isomers
    • C07C231/18—Preparation of optical isomers by stereospecific synthesis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Epidemiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SI200731603T 2006-06-19 2007-06-08 Postopek za izdelavo 2-(4-(3- in 2-fluorobenziloksi)benzilamino)propanamidov SI2029524T1 (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP06012565 2006-06-19
EP07764601.6A EP2029524B1 (en) 2006-06-19 2007-06-08 Process for the production of 2- [4 - ( 3- and 2-fluorobenzyloxy) benzylamino] propan amides
PCT/EP2007/005105 WO2007147491A1 (en) 2006-06-19 2007-06-08 Process for the production of 2- [4 - ( 3- and 2-flu0r0benzyl0xy) benzylamin0] propan amides

Publications (1)

Publication Number Publication Date
SI2029524T1 true SI2029524T1 (sl) 2015-03-31

Family

ID=37101658

Family Applications (2)

Application Number Title Priority Date Filing Date
SI200731603T SI2029524T1 (sl) 2006-06-19 2007-06-08 Postopek za izdelavo 2-(4-(3- in 2-fluorobenziloksi)benzilamino)propanamidov
SI200731854A SI2474521T1 (sl) 2006-06-19 2007-06-08 2-(4-(3- in 2-fluorobenziloksi)benzilamino)propanamidi z visoko stopnjo čistoče za uporabo kot zdravila in farmacevtske formulacije, ki jih vsebujejo

Family Applications After (1)

Application Number Title Priority Date Filing Date
SI200731854A SI2474521T1 (sl) 2006-06-19 2007-06-08 2-(4-(3- in 2-fluorobenziloksi)benzilamino)propanamidi z visoko stopnjo čistoče za uporabo kot zdravila in farmacevtske formulacije, ki jih vsebujejo

Country Status (26)

Country Link
US (2) US8076515B2 (https=)
EP (2) EP2474521B1 (https=)
JP (2) JP5240476B2 (https=)
KR (2) KR101491541B1 (https=)
CN (2) CN101472880B (https=)
AR (1) AR061510A1 (https=)
AU (1) AU2007263328C1 (https=)
BR (1) BRPI0712936B8 (https=)
CA (1) CA2653012C (https=)
CY (2) CY1115951T1 (https=)
DK (2) DK2029524T3 (https=)
EA (2) EA017123B1 (https=)
ES (2) ES2602069T3 (https=)
HR (2) HRP20150136T1 (https=)
HU (1) HUE030233T2 (https=)
IL (1) IL195294A (https=)
LT (1) LT2474521T (https=)
MX (2) MX2008015704A (https=)
NO (2) NO342018B1 (https=)
NZ (2) NZ595737A (https=)
PL (2) PL2029524T3 (https=)
PT (2) PT2474521T (https=)
RS (2) RS53824B1 (https=)
SI (2) SI2029524T1 (https=)
TW (2) TWI393700B (https=)
WO (1) WO2007147491A1 (https=)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2004266494B2 (en) * 2003-08-25 2010-04-08 Newron Pharmaceuticals, Spa Alpha-aminoamide derivatives useful as anti-inflammatory agents
HUE030233T2 (en) * 2006-06-19 2017-04-28 Newron Pharm Spa High purity 2- [4- (3- and 2-fluorobenzyloxy) benzylamino] propanamides for use as medicaments and pharmaceutical compositions containing them
CA2936209C (en) * 2007-12-11 2020-02-11 Newron Pharmaceuticals S.P.A. Process for the production of 2-[4-(3- or 2-fluorobenzyloxy)benzylamino]propanamides with high purity degree
EP2314569A1 (en) 2009-10-22 2011-04-27 Merck Patent GmbH Novel polymorphic forms of (S)-2-[4-(3-Fluoro-benzyloxy)-benzylamino]-propionamide mesylate salt and processes of manufacturing thereof
JP5808392B2 (ja) * 2010-04-27 2015-11-10 ニユーロン・フアーマシユーテイカルズ・エツセ・ピー・アー ラルフィナミドメタンスルホネート塩またはそのｒ−エナンチオマーの製造方法
WO2014086704A1 (en) 2012-12-03 2014-06-12 F. Hoffmann-La Roche Ag Substituted isoxazole amide compounds as inhibitors of stearoyl-coa desaturase 1 (scd1)
WO2014178083A1 (en) 2013-05-03 2014-11-06 Council Of Scientific & Industrial Research An improved synthesis of anti-parkinson agent
CN104292128A (zh) * 2014-07-01 2015-01-21 南京正科制药有限公司 一种沙芬酰胺晶型a
JP6466109B2 (ja) * 2014-09-09 2019-02-06 東ソー・ファインケム株式会社 ２−ベンジルオキシ−５−（トリフルオロメチル）ピリミジン誘導体及びその製造方法
CN105017060B (zh) * 2015-07-03 2017-06-16 南京正大天晴制药有限公司 一种沙芬酰胺新晶型及其制备方法
CN106365966A (zh) * 2015-07-24 2017-02-01 上海医药集团股份有限公司 一种苄基芳基醚的制备方法
CN105061245A (zh) * 2015-08-25 2015-11-18 成都维恒医药科技有限公司 一种高纯度沙芬酰胺的制备方法
CN106220525A (zh) * 2016-07-31 2016-12-14 合肥远志医药科技开发有限公司 一种工业化沙芬酰胺甲磺酸盐的制备方法
CN106336363B (zh) * 2016-08-22 2018-10-30 上海医药集团股份有限公司 一种沙芬酰胺甲磺酸盐晶型c及其制备方法
CN106565521B (zh) * 2016-08-24 2019-03-08 浙江美诺华药物化学有限公司 (s)-2-[3-(3-氟苄基)-4-(3-氟苄氧基)苄氨基]丙酰胺及其盐的制备方法
CN106596828B (zh) * 2016-12-15 2018-09-25 扬子江药业集团有限公司 一种甲磺酸沙芬酰胺有关物质的检测方法
CN107271600B (zh) * 2017-07-28 2019-01-25 成都百裕制药股份有限公司 一种4-(3-氟苄氧基)苯甲醛中异构体杂质含量的检测方法
CN107759487A (zh) * 2017-11-23 2018-03-06 江苏恒盛药业有限公司 一种沙芬酰胺盐酸盐及其一种晶型以及制备方法
CN107857713A (zh) * 2017-11-23 2018-03-30 江苏恒盛药业有限公司 一种沙芬酰胺氢溴酸盐及其一种晶型
WO2019167085A1 (en) * 2018-03-01 2019-09-06 Msn Laboratories Private Limited, R&D Center Process for the preparation of (s)-2-[[4-[(3-fluorophenyl)methoxy]phenyl]methyl]amino propanamide methanesulfonate
US11111208B2 (en) 2019-06-17 2021-09-07 RK Pharma Solutions LLC Process for the preparation of safinamide mesylate intermediate
ES2977486T3 (es) * 2019-08-06 2024-08-26 Medichem Sa Proceso para preparar safinamida
CN111122736B (zh) * 2019-12-30 2021-03-12 北京鑫开元医药科技有限公司海南分公司 一种用于检测布瓦西坦中间体中对映异构体的方法
CN113214097B (zh) * 2020-01-21 2022-08-30 厦门大学 治疗阿尔茨海默病的化合物
CN112028754A (zh) * 2020-06-17 2020-12-04 浙江美诺华药物化学有限公司 一种甲磺酸沙芬酰胺中间体的制备方法
CN114088830B (zh) * 2021-11-10 2022-09-23 石家庄四药有限公司 一种4-(3-氟苄氧基)苯甲醛中异构体的检测方法
CN117923998A (zh) * 2022-10-24 2024-04-26 中国石油化工股份有限公司 苯甲醛及其衍生物的制备方法
CN116008439B (zh) * 2023-02-20 2023-10-27 山东绿叶制药有限公司 一种检测2,6-二氧杂螺[4,5]癸烷类化合物或其盐中杂质的方法
CN121548409A (zh) 2023-07-25 2026-02-17 印塔斯制药有限公司 沙芬酰胺的口腔分散药物固体剂型

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL94466A (en) * 1989-05-25 1995-01-24 Erba Carlo Spa Pharmaceutical preparations containing the history of A-amino carboxamide N-phenylalkyl are converted into such new compounds and their preparation
GB9727523D0 (en) 1997-12-31 1998-02-25 Pharmacia & Upjohn Spa Alpha-aminoamide derivatives useful as analgesic agents
EP0974351A3 (en) * 1998-04-24 2000-12-13 Jouveinal Medicament for preventing and treating gastrointestinal damage
WO2001074779A1 (en) 2000-03-31 2001-10-11 Euro-Celtique S.A. Aminopyridines and their use as anticonvulsants and sodium channel blockers
IL160523A0 (en) * 2001-09-03 2004-07-25 Newron Pharm Spa PHARMACEUTICAL COMPOSITION COMPRISING GABAPENTIN OR AN ANALOGUE THEREOF AND AN alpha-AMINOAMIDE AND ITS ANALGESIC USE
EP1438956A1 (en) 2003-01-16 2004-07-21 Newron Pharmaceuticals S.p.A. Alpha-aminoamide derivatives useful as antimigraine agents
US20040213842A1 (en) * 2003-01-30 2004-10-28 Dynogen Pharmaceuticals, Inc. Methods of treating gastrointestinal tract disorders using sodium channel modulators
EP1589959A2 (en) * 2003-01-30 2005-11-02 Dynogen Pharmaceuticals Inc. Methods of treating lower urinary tract disorders using sodium channel modulators
AR044007A1 (es) 2003-04-11 2005-08-24 Newron Pharmaceuticals Inc Metodos para el tratamiento de la enfermedad de parkinson
TW200507850A (en) * 2003-07-25 2005-03-01 Kyowa Hakko Kogyo Kk Pharmaceutical composition
AU2004266494B2 (en) 2003-08-25 2010-04-08 Newron Pharmaceuticals, Spa Alpha-aminoamide derivatives useful as anti-inflammatory agents
EP1524267A1 (en) 2003-10-15 2005-04-20 Newron Pharmaceuticals S.p.A. Substituted benzylaminoalkylene heterocycles
EP1557166A1 (en) * 2004-01-21 2005-07-27 Newron Pharmaceuticals S.p.A. Alpha-aminoamide derivatives useful in the treatment of lower urinary tract disorders
EP1588704A1 (en) 2004-04-22 2005-10-26 Newron Pharmaceuticals S.p.A. Alpha-aminoamide derivatives useful in the treatment of restless legs syndrome and addictive disorders
ATE471147T1 (de) 2004-09-10 2010-07-15 Newron Pharm Spa Verwendung von (r)-(halogenbenzyloxy)-benzylamino-propanamiden als natrium- und/oder calciumkanal- selektive modulatoren
EP1870097A1 (en) 2006-06-15 2007-12-26 Newron Pharmaceuticals S.p.A. Alpha-aminoamide derivatives useful in the treatment of cognitive disorders
HUE030233T2 (en) * 2006-06-19 2017-04-28 Newron Pharm Spa High purity 2- [4- (3- and 2-fluorobenzyloxy) benzylamino] propanamides for use as medicaments and pharmaceutical compositions containing them
CA2936209C (en) 2007-12-11 2020-02-11 Newron Pharmaceuticals S.P.A. Process for the production of 2-[4-(3- or 2-fluorobenzyloxy)benzylamino]propanamides with high purity degree
BRPI0821026A2 (pt) 2007-12-19 2015-06-16 Newron Pharmaceutical S P A Derivados de alfa-minoamidas úteis no tratamento de transtornos psiquiátricos

Also Published As

Publication number Publication date
BRPI0712936A2 (pt) 2012-12-18
AU2007263328A2 (en) 2009-02-19
US8278485B2 (en) 2012-10-02
DK2029524T3 (da) 2015-02-23
NO342018B1 (no) 2018-03-12
CY1118113T1 (el) 2017-06-28
CN103284984A (zh) 2013-09-11
TWI412512B (zh) 2013-10-21
KR101491541B1 (ko) 2015-02-09
JP5795342B2 (ja) 2015-10-14
EP2474521A1 (en) 2012-07-11
AU2007263328C1 (en) 2012-09-06
RS53824B1 (sr) 2015-06-30
AR061510A1 (es) 2008-09-03
DK2474521T3 (en) 2016-10-31
HUE030233T2 (en) 2017-04-28
EP2474521B1 (en) 2016-08-10
CN103284984B (zh) 2016-08-03
KR101410291B1 (ko) 2014-06-20
PT2029524E (pt) 2015-03-09
RS55464B1 (sr) 2017-04-28
US8076515B2 (en) 2011-12-13
BRPI0712936B8 (pt) 2021-05-25
KR20140027563A (ko) 2014-03-06
EP2029524A1 (en) 2009-03-04
ES2602069T3 (es) 2017-02-17
BRPI0712936B1 (pt) 2021-02-23
ES2527437T3 (es) 2015-01-26
NO20090231L (no) 2009-01-16
CN101472880A (zh) 2009-07-01
EA201101308A1 (ru) 2012-02-28
KR20090021392A (ko) 2009-03-03
US20120157712A1 (en) 2012-06-21
MX342698B (es) 2016-10-10
EA025326B1 (ru) 2016-12-30
US20090156678A1 (en) 2009-06-18
TW200815322A (en) 2008-04-01
EP2029524B1 (en) 2014-11-26
WO2007147491A1 (en) 2007-12-27
CN101472880B (zh) 2013-04-24
IL195294A (en) 2015-03-31
EA017123B1 (ru) 2012-10-30
NO20171916A1 (no) 2009-01-16
TW201313662A (zh) 2013-04-01
HRP20161456T1 (hr) 2016-12-16
TWI393700B (zh) 2013-04-21
MX2008015704A (es) 2009-01-09
NZ595737A (en) 2013-04-26
HK1130245A1 (en) 2009-12-24
CA2653012C (en) 2014-08-05
SI2474521T1 (sl) 2016-12-30
CY1115951T1 (el) 2017-01-25
AU2007263328A1 (en) 2007-12-27
JP2009541232A (ja) 2009-11-26
PL2029524T3 (pl) 2015-04-30
IL195294A0 (en) 2009-08-03
JP5240476B2 (ja) 2013-07-17
NZ572798A (en) 2011-11-25
EA200970028A1 (ru) 2009-06-30
AU2007263328B2 (en) 2012-03-22
NO342644B1 (no) 2018-06-25
JP2013139446A (ja) 2013-07-18
LT2474521T (lt) 2016-11-25
CA2653012A1 (en) 2007-12-27
PL2474521T3 (pl) 2017-01-31
HRP20150136T1 (xx) 2015-03-13
PT2474521T (pt) 2016-11-10

Similar Documents

Publication Publication Date Title
SI2029524T1 (sl) Postopek za izdelavo 2-(4-(3- in 2-fluorobenziloksi)benzilamino)propanamidov
IL189757A0 (en) Process for the production of amides
ZA200909030B (en) Method for the production of n-substituted (3-dihalomethyl-1-methyl-pyrazole-4-yl)carboxamides
IL191125A0 (en) Process for production of cinnamide derivative
IL184184A0 (en) Process for the purification of duloxetine hydrochloride
IL220430A0 (en) Process for the production of benzopyran-2-ol derivatives
EP2070935A4 (en) NOVEL COMPOUND, COMPOSITION COMPRISING SAME, AND PROCESS FOR PRODUCING POLYMERIZABLE AMIDE
AP2009004935A0 (en) New process for the synthesis of agomelatine
AP3167A (en) New process for the synthesis of agomelatine
IL208792A0 (en) Process for the preparation of amides
EP1861408A4 (en) PROCESS FOR PRODUCING HYDROCHLOROSILANES
EP2088136A4 (en) PROCESS FOR PRODUCING HYDROXYADAMANTANE-AMINE
IL187155A0 (en) Process for production of 4-biphenylazetidin-2-ones
ZA200905051B (en) Process for the synthesis of agomelatine
ZA200710066B (en) Process for production of 4-biphenylylazetidin-2-ones
HUP0500808A2 (en) Wrapped meat-product and process for production it
IL189354A0 (en) Process for the production of anilines
EP1951623A4 (en) METHOD AND APPARATUS FOR HIGH PURITY MAGNETINE FORMATION AND PRODUCT THEREOF
EP1947083A4 (en) PROCESS FOR THE PREPARATION OF ARALKYLOXYPYRROLIDINE DERIVATIVES
EP1864993A4 (en) METHOD FOR PRODUCING A GLUCOPYRANOSYLOXYPYRAZOLE DERIVATIVE
EP1903021A4 (en) PROCESS FOR THE PREPARATION OF FLUOROUS COMPOUNDS
PL1937662T3 (pl) Sposób wytwarzania duloksetyny
IL184639A0 (en) Process for the production of 2-(2-aminophenyl)-bicyclopropane derivatives
GB201013148D0 (en) Novel dioctatin derivatives and process for production thereof
ZA200801826B (en) Process for the production of amides